Navigation Links
Monitoring and control can limit side effects of promising cancer drugs

A new class of cancer drugs can be used effectively while minimizing hypertensive side effects if patients' blood pressure is closely monitored and controlled, a clinical panel has determined.

The panel brought oncologists, cardiologists and hypertension experts together to draft new recommendations for physicians prescribing angiogenesis inhibitors for the treatment of cancer. First approved in the mid-2000's, these drugs disrupt tumor growth by preventing the formation of new blood vessels, but also increase blood pressure in most patients.

Treating a patient's hypertension before starting the inhibitors and closely monitoring their blood pressure in the days after treatment begins can help physicians control this side effect, the panel concluded this month in the Journal of the National Cancer Institute. Those precautions may allow patients at higher risk for cardiovascular disease to benefit from these novel cancer treatments, authors said.

"This paper should impact practice today," said Michael Maitland, MD, PhD, assistant professor of medicine at the University of Chicago Medical Center and lead author on the commentary. "It should make things safer on average for patients, and will give physicians important guidance."

Several different angiogenesis inhibitors have been studied in clinical trials, and all cause an elevation of blood pressure in most patients. These drugs are also given with increased frequency to patients above 60 years old, a population with a high chance of pre-existing hypertension.

"Often the case is those patients aren't seeking medical attention for hypertension until they find that they have a tumor and need treatment for cancer," Maitland said. "If a patient is hypertensive, a physician should not dismiss that as irrelevant just because they have advanced cancer. We already know that ignoring co-morbidities in a cancer patient can generate as much risk for their long term survival as the stage of the cancer."

The panel recommended that a patient should be thoroughly screened before treatment with angiogenesis inhibitors. A risk assessment should be performed, similar to the cardiovascular assessment given patients before major surgery, Maitland said. Before treatment begins, blood pressure in high-risk patients should be reduced and maintained at less than140/90 mmHg, or even lower in patients with diabetes or chronic kidney disease.

A variety of antihypertensive drug classes can be used to lower a patient's blood pressure before or during treatment with angiogenesis inhibitors, but physicians should be aware of potential adverse interactions between the two drugs. Oncologists faced with complex cases of blood pressure management should consult colleagues more experienced in cardiology and hypertension, the panel advised.

"The recommendations put all of us on the same page," said George Bakris, MD, director of the Hypertensive Diseases Unit at the Medical Center and another author on the JNCI commentary. "It really is a seminal effort to provide some kind of general guidance and understanding of how these drugs work, what to do about their consequences, and how to successfully manage patients to make sure the outcome is ideal across the board."

Improved monitoring and treatment of hypertension during angiogenesis inhibitor treatment may open up the treatment to patients considered to be at high-risk for the side effect due to a history of cardiovascular disease or predisposition toward high blood pressure.

"We're not trying to keep anybody from getting these drugs, but there should be different levels of intensity and attention to the potential side effects based on what we know about hypertension and cardiovascular disease," Maitland said.

Further research is also underway to determine the mechanism of how angiogenesis inhibitors promote hypertension, studies that could further improve clinical management of the drugs' side effects.

"Those studies are not going to change therapy, but based on what they find, they may be able to perfect therapy and make it better," Bakris said. "This drug class has great potential for altering the natural history of many cancers. With this guidance, all physicians involved in the care of a cancer patient will be aware of monitoring blood pressure and signs of kidney injury and will know what to do if such problems arise."

"If carefully managed, I think these drugs are a huge move forward in our armory against cancer," Bakris said.

The commentary, "Initial assessment, surveillance, and management of blood pressure in patients receiving vascular endothelial growth factor signaling pathway inhibitors," appears in the May 5th issue of the Journal of the National Cancer Institute.


Contact: Robert Mitchum
University of Chicago Medical Center

Related medicine news :

1. Cost Savings from Mobile Health Monitoring to Reach $1.9 billion to $5.8 Billion Globally by 2014 says Juniper Research
2. New Diagnostic Testing Company, Blue Ocean Biomedical, Specializes In Automated, Load & Go Cell Analysis Systems For Immune Monitoring
3. Envisat monitoring changes in oil spill
4. New VKernel AppVIEW 1.0 for Monitoring and Identification of Capacity Bottlenecks in Critical Application VMs
5. CWRU study examines effectiveness of telemonitoring vital signs
6. Revenues from Mobile Health Monitoring to Reach $1.9 Billion Globally by 2014 Says Juniper Research
7. Six Degrees Launches ePulse - an Online Buzz Monitoring Tool
8. IESO, one of the Independent System Operators in North America, Selects MetricStream GRC for Monitoring Compliance to Electric Reliability Standards
9. Improved patient care with telemonitoring
10. The Results Are In: Users of BodyMedia's Wearable Body-Monitoring Technology Lose 3 Times More Weight
11. ANT+ and iTMP Announce the Digifit™ Ecosystem - The First iPhone™ Apps to Integrate Running, Cycling and Heart Rate Monitoring
Post Your Comments:
(Date:12/1/2015)... ... ... It’s official: Tattoo taboo is a thing of the past. One in five ... one in three aged 18 to 25 is inked). As tattoos transition to mainstream ... fact, RealSelf , the world’s largest community for learning and sharing information about ...
(Date:12/1/2015)... ... December 01, 2015 , ... The importance of volumetric breast ... focus of numerous abstracts accepted for presentation here, at the 101st Annual Radiology ... highlight the use of Volpara Solutions’ quantitative breast imaging software tools for providing ...
(Date:12/1/2015)... ... 01, 2015 , ... Visage accelerates mobile imaging results access ... of Pro Medicus Ltd. (ASX: PME), has announced they are demonstrating new work-in-progress ... (RSNA) 2015 annual meeting through December 3 in Chicago, Illinois, at Booth #1350, ...
(Date:12/1/2015)... ... 01, 2015 , ... McLean, VA., December 1, 2015 - ... per sprint agile development contract to support the National Geospatial-Intelligence Agency's (NGA) IT ... software engineering, infrastructure, as well as operations and sustainment support to the NGA’s ...
(Date:12/1/2015)... TN (PRWEB) , ... December 01, 2015 , ... ... from the Field for Effective Post-Affiliation Integration ,” addresses a main “pain point” ... to deliver the anticipated results, once a deal is signed. This quick-read ...
Breaking Medicine News(10 mins):
(Date:12/1/2015)... , Dec. 1, 2015  Eyeon Therapeutics has ... dry eye treatments based on a charged hydrophilic ... delivery CDMO.  The product has been shown to ... previously published.  Mark Mitchnick , MD, CEO ... protection to additional polymers in conjunction with a ...
(Date:12/1/2015)... Dec. 1, 2015  Athletic apparel company ... agreed to pay $1.35 million to settle Federal ... company,s copper-infused compression clothing would relieve severe and ... other diseases. Tommie Copper,s ... company and its founder and chairman Thomas ...
(Date:12/1/2015)... de diciembre de 2015  AccuTEC Blades, ... de precisión, develó hoy un nuevo logo ... marca. El nuevo logo destaca la experiencia ... ingeniería de productos con cuchillas donde "el ... --> ...
Breaking Medicine Technology: